News

Monday, 01. July 2013

ARIKACE Meets Primary Endpoint of Non-Inferiority to TOBI

ARIKACE Meets Primary Endpoint of Non-Inferiority to TOBI in Phase 3 Clinical Trial in Europe and Canada to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients

Logo insmed

ARIKACE Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. FDA for the Treatment of Non-Tuberculous Mycobacteria Lung Infections

Conference Call to be Held Monday, July 1st at 8:00 a.m. Eastern Time

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases that are often life-threatening, announces positive developments in both of its clinical development programs for ARIKACE, or liposomal amikacin for inhalation (LAI).